The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jansen, R.
Right arrow Articles by Wiltrout, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jansen, R.
Right arrow Articles by Wiltrout, R. H.

The Journal of Immunology, Vol 147, Issue 10 3342-3347, Copyright © 1991 by American Association of Immunologists

ARTICLES

Effects of recombinant transforming growth factor-beta 1 on hematologic recovery after treatment of mice with 5-fluorouracil

R Jansen, G Damia, N Usui, J Keller, H Futami, H Goey, TT Back, DL Longo, FW Ruscetti and RH Wiltrout
Laboratory of Experimental Immunology, NCI-FCRDC, MD 21702-1201.

Transforming growth factor beta 1 (TGF-beta 1) has been shown to inhibit bone marrow colony formation after in vitro treatment as well as after in vivo administration to normal mice. These data suggest that TGF-beta might either protect, or further depress, progenitor cell levels in mice exposed to a cell cycle-active drug such as 5- fluorouracil (5FU). rTGF-beta 1 was administered repeatedly by either the i.v. or i.p. routes to mice during the hyperproliferative state of the bone marrow that occurs 7 to 9 days after the i.v. administration of 150 mg/kg 5FU. The formation of both multilineage and the more differentiated (CFU-c) colonies was inhibited by 20 to 40%/culture, and 66 to 93%/mouse. When multiple doses of rTGF-beta 1 were administered systemically immediately before the injection of 5FU, the resulting rebound in the number of CFU-c and multilineage colonies containing granulocyte, erythroid, megakaryocyte, and macrophage lineage colonies per culture was markedly inhibited by 30 to 77%, whereas the total number of CFU per mouse was inhibited up to 93%. This effect was maximal when rTGF-beta 1 was administered at daily doses of greater than or equal to 5 micrograms/mouse for at least 3 days. This inhibition of the recovery of the bone marrow from 5FU treatment induced by rTGF-beta 1 was a delayed transient response because by day 16 the progenitor cell numbers and bone marrow cellularity were identical to the 5FU-treated marrow controls.


This article has been cited by other articles:


Home page
 BloodHome page
M. Dong and G. C. Blobe
Role of transforming growth factor-beta in hematologic malignancies
Blood, June 15, 2006; 107(12): 4589 - 4596.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Satterwhite, R. L. White, N. Matsunami, and K. L. Neufeld
Inhibition of Topoisomerase II{{alpha}} Expression by Transforming Growth Factor-{beta}1 Is Abrogated by the Papillomavirus E7 Protein
Cancer Res., December 1, 2000; 60(24): 6989 - 6994.
[Abstract] [Full Text]

Home page
 BloodHome page
N. O. Fortunel, A. Hatzfeld, and J. A. Hatzfeld
Transforming growth factor-beta : pleiotropic role in the regulation of hematopoiesis
Blood, September 15, 2000; 96(6): 2022 - 2036.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J.D. Cashman, I. Clark-Lewis, A.C. Eaves, and C.J. Eaves
Differentiation Stage-Specific Regulation of Primitive Human Hematopoietic Progenitor Cycling by Exogenous and Endogenous Inhibitors in an In Vivo Model
Blood, December 1, 1999; 94(11): 3722 - 3729.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1991 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1991 by The American Association of Immunologists, Inc. All rights reserved.